BioCentury | May 28, 2020
Distillery Therapeutics

Reducing kidney damage in lupus by targeting HIF1A

DISEASE CATEGORY: Autoimmune disease INDICATION: Lupus Inhibiting HIF1A could treat lupus by reducing hypoxia-mediated kidney damage by T cells. In renal biopsies from systemic lupus erythematosus patients, tissue with high T cell infiltration had higher...
BC Innovations | Dec 17, 2015
Distillery Therapeutics

Therapeutics: Pyruvate dehydrogenase kinase 2 (PDK2); PDK4

Neurology INDICATION: Pain Mouse studies suggest dual PDK2 / PDK4 inhibitors could help treat inflammatory pain. In mice, intraplantar administration of an inflammatory adjuvant increased hindpaw expression of PDK2 and PDK4 compared with vehicle. In...
BC Innovations | May 22, 2014
Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Restenosis Pyruvate dehydrogenase kinase 2 (PDK2) Rodent, rabbit and porcine studies suggest inhibiting PDK2 in coronary artery transplants could prevent restenosis. In rodent and...
BC Week In Review | Jun 3, 1996
Company News

Albert Einstein College of Medicine other research news

Researchers reported the discovery of a second gene associated with autosomal dominant polycystic kidney disease (ADPKD). PKD, the most common of all life-threatening genetic diseases, causes the development of fluid-filled cysts in the kidney that...
Items per page:
1 - 4 of 4